MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toth, M.
Right arrow Articles by Shenk, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toth, M.
Right arrow Articles by Shenk, T.

Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription

M Toth and T Shenk

Howard Hughes Medical Institute, Department of Molecular Biology, Princeton University, New Jersey 08544-1014.

Prolonged exposure to an agonist results in a progressive loss of most G protein-coupled receptors, whereas exposure to an antagonist causes increased receptor response. The 5-hydroxytryptamine (5-HT)2 receptor is down-regulated by agonists but, paradoxically, antagonists can also elicit a decrease in receptor density. Here we show that long term treatment with serotonin or mianserin, an antagonist and antidepressant, results in reduced levels of both the 5-HT2 receptor and its RNA. Antagonist-induced down-regulation requires the presence of the 5-HT2 receptor, it occurs at the level of transcription, and it is mediated by a drug response sequence in the 5' flanking region of the 5-HT2 receptor gene. The effect of mianserin might result, at least in part, from its ability to modulate transcription.

Volume 45, Issue 6, pp. 1095-1100, 06/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
N. R. S. Hanley and J. G. Hensler
Mechanisms of Ligand-Induced Desensitization of the 5-Hydroxytryptamine2A Receptor
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 468 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. W. Stewart, F. M. Quitkin, P. J. McGrath, J. Amsterdam, M. Fava, J. Fawcett, F. Reimherr, J. Rosenbaum, C. Beasley, and P. Roback
Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo
Arch Gen Psychiatry, April 1, 1998; 55(4): 334 - 343.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. Sibille, Z. Sarnyai, D. Benjamin, J. Gal, H. Baker, and M. Toth
Antisense Inhibition of 5-Hydroxytryptamine2a Receptor Induces an Antidepressant-Like Effect in Mice
Mol. Pharmacol., December 1, 1997; 52(6): 1056 - 1063.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics